Cellectis S.A Stock-Based Compensation Growth & History (CLLS)

Cellectis S.A's stock-based compensation was $6.1M for fiscal 2025.

View full Cellectis S.A company overview

Cellectis S.A annual stock-based compensation history

Cellectis S.A annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$6.1M$2.9M+92.93%
20242024-12-31$3.2M−$2.1M−39.48%
20232023-12-31$5.2M−$810,000−13.40%
20222022-12-31$6.0M−$5.5M−47.42%
20212021-12-31$11.5M$1.5M+14.61%
20202020-12-31$10.0M−$16.9M−62.69%
20192019-12-31$26.9M−$7.7M−22.23%
20182018-12-31$34.6M−$14.4M−29.35%
20172017-12-31$48.9M−$9.7M−16.54%
20162016-12-31$58.6M$25.2M+75.50%
20152015-12-31$33.4M

Cellectis S.A stock-based compensation trends

Over the last five fiscal years, Cellectis S.A's stock-based compensation decreased from $10.0M to $6.1M, a change of −$3.9M. The latest reported quarter, Q2 2026, shows $2.3M.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cellectis S.A source filings ↗

Community posts

It’s quiet here.

No posts about CLLS yet. Start the conversation.

Write the first post